Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective MRI connectomics study of migraine patients treated with Fremanezumab
2020-004509-30Phase 4Active
- Sponsor
- Fundación Instituto de Ciencias de la Salud de Castilla y León
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of fremanezumab in migraine, sponsored by Fundación Instituto de Ciencias de la Salud de Castilla y León. Primary endpoints: Morphometric MRI parameters change from baseline and Brain changes after three months associated with outcomes. Started Feb 2021; status: active.
02
Drugs
fremanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on 2020-004509-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004509-30.